Compare ACDC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | KURA |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2021 | 2015 |
| Metric | ACDC | KURA |
|---|---|---|
| Price | $4.67 | $11.37 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $5.50 | ★ $25.56 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,941,800,000.00 | $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | $11.50 | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $3.08 | $7.36 |
| 52 Week High | $8.22 | $13.90 |
| Indicator | ACDC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 44.23 |
| Support Level | $4.73 | $8.45 |
| Resistance Level | $5.49 | $11.40 |
| Average True Range (ATR) | 0.32 | 0.50 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 29.66 | 10.44 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.